An observational study in Shoulder Surgery, Shoulder Pain and Shoulder Injuries, sponsored by Duke University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Duke University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Shoulder Pain with a site in United States — 21 open to participants now, 28 under way, none of them phase 3. Shoulder Pain · United States.
Among the 146 studies in Shoulder Pain with a site in United States, this one is the 13th largest by planned enrollment of the 24 observational ones that give a count, is one of 9 that started in 2021, is one of 24 observational ones, reaches primary completion later than 18 of the 27 other live ones, and was the 100th registered.
738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.
Browse Shoulder Pain studies →21 of the 146 studies in Shoulder Pain with a site in United States are open now. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–45 · Healthy volunteers
Cedars-Sinai Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
Prisma Health-Upstate · Sites in United States
Ages 21–65 · Women only
Lisa Griffin · Sites in United States
Ages 60+
University of Florida · Sites in United States
Ages 18–50
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 8 · Phase 3 10 · Phase 4 21
First in 2003; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 84 across 135 observational studies indexed under Shoulder Pain.
Median enrollment 50 across the 122 interventional studies, 65 across the 24 observational. Of the 101 that completed or were terminated, 32 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 146 have an industry lead sponsor. The 10 most frequent:
Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.
Duke University has 4 studies filed under Shoulder Pain — fewer than ten, so there is no comparison to draw.
12 of the studies in Shoulder Pain with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07851233Rothman Institute OrthopaedicsPatient Education and Sling Use After Shoulder Surgery | 2026-11-30 |
| NCT06039345University of UtahShoulder RFA Pilot Study | 2026-12 |
| NCT07101250Prisma Health-UpstatePreoperative Acetazolamide | 2026-12-01 |
| NCT03653455Rush University Medical CenterPatient Outcomes Collection: How Can we do Better? | 2026-12-31 |
| NCT07400146Cedars-Sinai Medical CenterBupivacaine With Epinephrine Over Diaphragm in Laparoscopy | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 146 studies in Shoulder Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational study aims to evaluate the incidence of hemidiaphragmatic paralysis in patients receiving interscalene brachial plexus nerve block with prolonged neural blockade. English speaking American Society of Anesthesiologists (ASA) 1-3 patients ages 18-80 receiving prolonged interscalene nerve block will be randomized into 3 groups: first group receiving a perineural catheter infusing 0.2% ropivacaine; the second group receiving a single shot injection of 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine and the third receiving 20mL liposomal bupivacaine plus 5mL bupivacaine (to be determined by the attending anesthesiologist).Primary outcome will be incidence of hemidiaphragmatic paralysis postoperative day 1 as measured by point of care (POCUS) ultrasound.
This prospective observational study aims to evaluate the incidence of hemidiaphragmatic paralysis in patients receiving interscalene brachial plexus nerve block with prolonged neural blockade. English speaking ASA 1-3 patients ages 18-80 receiving prolonged interscalene nerve block will be randomized into 3 groups first group receiving a perineural catheter infusing 0.2% ropivacaine; the second group receiving a single shot injection of 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine and the third group receiving 20mL liposomal bupivacaine plus 5mL bupivacaine (to be determined by the attending anesthesiologist). Primary outcome will be incidence of hemidiaphragmatic paralysis postoperative day 1 as measured by point of care (POCUS) ultrasound. Secondary outcomes include incidence of hemidiaphragmatic paralysis as measured by point of care ultrasound (POCUS) in the immediate postoperative period, postoperative day (POD) 1, POD2, and POD3 and noninvasive measures of pulmonary gas exchange at pre-op, post-op, POD1, POD2, and POD3. Additionally, the investigators will look at pain scores (scale of 0-10) and opioid consumption (in oral morphine equivalents) at previously defined time points listed above. Furthermore, the investigators will record known side effects of interscalene blocks including hoarseness and Horner's syndrome.
Patients ages 18-80 undergoing shoulder surgery per standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placement of preoperative continuous perineural catheter using 25 milliliters (mL) 0.5% ropivacaine with 1:400,000k ropivacaine for initial block and 0.2% ropivacaine for continuous infusion.
Diagnostic Test: Ultrasound · Drug: Ropivacaine · Device: MediPines AGM100 Advanced Respiratory Monitoring System
Placement of preoperative single shot using 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine
Diagnostic Test: Ultrasound · Drug: Bupivacaine · Device: MediPines AGM100 Advanced Respiratory Monitoring System
Placement of preoperative single shot using 20mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine
Diagnostic Test: Ultrasound · Drug: Bupivacaine · Device: MediPines AGM100 Advanced Respiratory Monitoring System
Ultrasound guided evaluation of diaphragm ipsilateral to the block side.
Local anesthetic (numbing drug)
Also known as: Naropin
Local anesthetic (numbing drug)
Also known as: Liposomal bupivacaine, Exparel, Marcaine
Non-invasive respiratory monitor to measure oxygenation and ventilation parameters
Also known as: non-invasive respiratory monitor
Hemidiaphragmatic paralysis - ipsilateral - postoperative day (POD) 1
Ultrasound guided evaluation of ipsilateral hemidiaphragmatic paralysis POD1
Time frame: 24 hours
Hemidiaphragmatic paralysis - ipsilateral - PACU, POD2, POD3
Ultrasound guided evaluation of ipsilateral hemidiaphragmatic paralysis in PACU, POD2, and POD 3
Time frame: up to 72 hours
Noninvasive pulmonary measures of gas exchange
Noninvasive pulmonary measures of gas exchange
Time frame: up to 72 hours
Pain scores
Numerical Rating Scale (NRS) 11 pain scores (0-10; 0=no pain, 10=worst pain ever) at Post Anesthesia Care Unit (PACU), POD1, POD2, POD3
Time frame: up to 72 hours
Opioid consumption
Opioid consumption in Oral Morphine Equivalents (OMEs) at PACU, POD1, POD2, POD3
Time frame: up to 72 hours
Hoarseness
Incidence of recurrent laryngeal nerve palsy (subjective)
Time frame: up to 72 hours
Horner's Syndrome
Incidence of Horner's Syndrome
Time frame: up to 72 hours
Plan to share: No — Individual participant data will not be shared; patients will be deidentified and no personal information or medical records used once patient has completed the study.
No publications or documents are linked to this record.
Started Oct 2021 (actual). Primary completion is estimated for Aug 2027, 70 months after the start.
Of 49 non-industry observational studies under Shoulder Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 24. This study's planned 70 months is above that.
Counting every sponsor, half of 54 studies reached it within 12 months; a quarter within 4 and three quarters within 35.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Aug 2026 → Aug 2027 and completion Aug 2026 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.